ZTrials

https://www.empr.com/home/news/fda-approves-new-atypical-antipsychotic-caplyta-to-treat-schizophrenia-in-adults/

FDA Approves Caplyta for Schizophrenia - MPR The Food and Drug Administration (FDA) has approved Caplyta (lumateperone; Intra-Cellular Therapies), an atypical antipsychotic, for the treatment of schizophrenia in adult patients. The approval was based on results from 2 double-blind, placebo-controlled trials (Study 1 [N=335] and Study 2 [N=450]...

Take action! Reach out to your members of Congress.

Urge Your Members of Congress to Cosponsor PACT Act

Enter Your Information to Find Your Officials and Candidates, and Access a Voter Toolkit with Voter Registration Information and More!

bethematch.p2a.co Enter your information to learn who represents you!

FDA Approves Olaparib for gBRCAm Metastatic Pancreatic Adenocarcinoma

News & Analysis News & Analysis